How should chronic bronchitis be managed, including smoking cessation, vaccinations, bronchodilator therapy (short‑acting β2‑agonist and LABA (long‑acting β2‑agonist)/LAMA (long‑acting muscarinic antagonist) combination), inhaled corticosteroids for frequent exacerbations, pulmonary rehabilitation, supplemental oxygen for hypoxemia, and treatment of acute exacerbations with oral prednisone and macrolide antibiotics?

Management of Chronic Bronchitis

Smoking cessation is the single most critical intervention and must be aggressively pursued at every clinical encounter, as it is the only intervention that slows disease progression and reduces mortality. 1

Initial Pharmacologic Management

For Symptomatic Patients Without Frequent Exacerbations (Group A/B)

• Start with LAMA monotherapy as first-line treatment, as it is superior to LABA monotherapy for preventing exacerbations (risk ratio 0.77,95% CI 0.66-0.90) 2
• LABA monotherapy is an acceptable alternative but less preferred option for patients with low exacerbation risk (≤1 moderate exacerbation in the last year without hospital admission) 2
• If symptoms persist on monotherapy, escalate to LAMA/LABA dual therapy rather than adding ICS 1, 2
• For patients with severe breathlessness, initial therapy with LAMA/LABA combination may be considered from the outset 1

For Patients With Frequent Exacerbations (Group C/D)

• Initiate LAMA/LABA combination therapy as first-line treatment because dual bronchodilation demonstrates superior exacerbation prevention and symptom control compared to monotherapy 1, 2
• LAMA/LABA combination is superior to LABA/ICS combination in preventing exacerbations and improving patient-reported outcomes in high-risk patients 1

When to Add Inhaled Corticosteroids

ICS should ONLY be added to LABA/LAMA therapy in highly selected patients—never use ICS as monotherapy. 2

Specific Criteria for ICS Addition:

• Blood eosinophil count ≥300 cells/µL AND history of ≥2 moderate exacerbations per year despite appropriate long-acting bronchodilator therapy 2
• History of hospitalizations for COPD exacerbations 2
• Concomitant asthma or asthma-COPD overlap syndrome 2, 3
• Chronic bronchitis phenotype with FEV1 <50% predicted and ≥2 exacerbations per year 2

Critical caveat: Triple therapy (LAMA/LABA/ICS) increases pneumonia risk significantly (3.3% versus 1.9%, OR 1.74) 4, and ICS use may increase risk of nontuberculous mycobacterial infection, particularly in older females and never-smokers 5

Add-On Therapies for Refractory Patients

For Patients Still Exacerbating Despite Triple Therapy:

• Add azithromycin maintenance therapy (250 mg daily or 500 mg three times weekly) for former smokers with continued exacerbations 1, 6
• Mandatory safety monitoring: baseline and periodic hearing tests, ECG screening for QT prolongation, monitoring for bacterial resistance 6

For Chronic Bronchitis Phenotype:

• Consider roflumilast (PDE4 inhibitor) for patients with severe-to-very severe COPD, chronic bronchitis, and continued exacerbations despite LABA/LAMA/ICS 1, 6
• Dosing: start at 250 mcg daily for 4 weeks, then increase to 500 mcg daily 6

Non-Pharmacologic Management

Essential Interventions:

• Pulmonary rehabilitation should be included for all symptomatic patients, particularly those with dyspnea or impaired exercise capacity 7
• Supplemental oxygen for patients with documented hypoxemia (typically PaO2 <55 mmHg or oxygen saturation <88%) 8
• Influenza and pneumococcal vaccinations are mandatory 9
• Nutritional support and hydration 8

Management of Acute Exacerbations

Systemic Corticosteroids:

• Use oral prednisone for acute exacerbations (typically 40 mg daily for 5-7 days) 10
• Never use long-term oral corticosteroids for stable COPD—they provide no benefit and cause significant harm 1, 10
• Prednisone should be given in the morning to minimize HPA axis suppression 10

Antibiotic Therapy:

• Reserve antibiotics for patients with at least one cardinal symptom (increased dyspnea, sputum production, or sputum purulence) AND one risk factor (age ≥65 years, FEV1 <50% predicted, ≥4 exacerbations in 12 months, or comorbidities) 11
• For moderate severity: newer macrolide, extended-spectrum cephalosporin, or doxycycline 11
• For severe exacerbations: high-dose amoxicillin/clavulanate or respiratory fluoroquinolone 11

Critical Pitfalls to Avoid

• Do not use ICS monotherapy—it increases adverse events without improving outcomes 2
• Do not routinely add ICS to all patients on LABA/LAMA—this is a common error in clinical practice despite guideline recommendations 12
• Do not continue long-term oral corticosteroids—there is no role for chronic systemic steroid therapy in stable COPD 1, 10
• Do not ignore pneumonia risk with ICS use—particularly in older patients with severe disease 3, 4